Ani Pharmaceuticals (ANIP) Receivables - Net (2012 - 2026)
Ani Pharmaceuticals (ANIP) posted Receivables - Net of $255.4 million for Q1 2026, down 9.13% sequentially from $281.1 million in Q4 2025, and up 15.93% YoY from $220.3 million in Q1 2025.
Ani Pharmaceuticals (ANIP) Receivables - Net (2012 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Receivables - Net for 15 years, with the latest figure at $255.4 million in Q1 2026.
- Quarterly Receivables - Net rose 15.93% year-over-year to $255.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $255.4 million (up 15.93% YoY) and the FY2025 annual result came in at $281.1 million, up 26.77% from the prior year.
- Receivables - Net slipped to $255.4 million in Q1 2026 per ANIP's latest filing, from $281.1 million in the prior quarter.
- Over five years, Receivables - Net peaked at $281.1 million in Q4 2025 and troughed at $131.6 million in Q1 2022.
- A 5-year average of $192.2 million and a median of $174.7 million in 2023 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2024: Receivables - Net surged 62.35% in 2022, then declined 3.95% in 2024.
- Over 5 years, Receivables - Net stood at $165.4 million in 2022, then slipped by 2.03% to $162.1 million in 2023, then jumped by 36.8% to $221.7 million in 2024, then climbed by 26.77% to $281.1 million in 2025, then slipped by 9.13% to $255.4 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $255.4 million, $281.1 million, and $252.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 274.47 Mn |
| Jun 30, 2026 | 274.47 Mn |
| Mar 31, 2026 | 255.43 Mn |
| Mar 31, 2026 | 255.43 Mn |
| Dec 31, 2025 | 281.08 Mn |
| Dec 31, 2025 | 281.08 Mn |
| Sep 30, 2025 | 252.62 Mn |
| Sep 30, 2025 | 252.62 Mn |
| Jun 30, 2025 | 225.65 Mn |
| Jun 30, 2025 | 225.65 Mn |
| Mar 31, 2025 | 220.33 Mn |
| Mar 31, 2025 | 220.33 Mn |
| Dec 31, 2024 | 221.73 Mn |
| Dec 31, 2024 | 221.73 Mn |
| Sep 30, 2024 | 196.36 Mn |
| Sep 30, 2024 | 196.36 Mn |
| Jun 30, 2024 | 166.09 Mn |
| Jun 30, 2024 | 166.09 Mn |
| Mar 31, 2024 | 172.42 Mn |
| Mar 31, 2024 | 172.42 Mn |